









市场行情
/
股票
/
nasdaq-rapt
/

RAPT Therapeutics Inc

RAPT

35.420USD

-0.420-1.17%

收盘 12/26, 16:00（美东）报价延迟15分钟

597.02M总市值

亏损市盈率 TTM



RAPT Therapeutics Inc

35.420

-0.420-1.17%

概览公司财务分析

概览

公司

财务

分析

关于 RAPT Therapeutics Inc 公司

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.

RAPT Therapeutics Inc简介



公司代码RAPT

公司名称RAPT Therapeutics Inc

上市日期Oct 31, 2019

CEOWong (Brian)

员工数量68

证券类型Ordinary Share

年结日Oct 31

公司地址561 Eccles Ave

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94080

电话16504899000

网址https://rapt.com/

公司代码RAPT

上市日期Oct 31, 2019

CEOWong (Brian)

RAPT Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Scott N. Braunstein, M.D.

Independent Director

Dr. Ashley Dombkowski, Ph.D.

Independent Director

Dr. Michael F. Giordano, M.D.

Independent Director

Dr. William (Bill) Ho, M.D., Ph.D.

Chief Medical Officer

Dr. Mary Ann Gray, Ph.D.

Independent Director

Ms. Lori Lyons-Williams

Independent Chairman of the Board

Dr. Brian Wong, M.D., Ph.D.

President, Chief Executive Officer, Director

Dr. Dirk Brockstedt, Ph.D.

Chief Scientific Officer

Mr. Rodney K. B. Young

Chief Financial Officer

Ms. Linda Kozick

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Scott N. Braunstein, M.D.

Independent Director

Dr. Ashley Dombkowski, Ph.D.

Independent Director

Dr. Michael F. Giordano, M.D.

Independent Director

Dr. William (Bill) Ho, M.D., Ph.D.

Chief Medical Officer

Dr. Mary Ann Gray, Ph.D.

Independent Director

Ms. Lori Lyons-Williams

Independent Chairman of the Board

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Medicxi Ventures (UK) LLP

10.08%

Forbion Capital Partners

6.62%

TCG Crossover Management, LLC

5.90%

Foresite Capital Management, LLC

5.64%

RTW Investments L.P.

5.31%

其他

66.45%

持股股东

占比

Medicxi Ventures (UK) LLP

10.08%

Forbion Capital Partners

6.62%

TCG Crossover Management, LLC

5.90%

Foresite Capital Management, LLC

5.64%

RTW Investments L.P.

5.31%

其他

66.45%

股东类型

持股股东

占比

Venture Capital

17.34%

Investment Advisor

15.93%

Hedge Fund

12.00%

Private Equity

10.22%

Investment Advisor/Hedge Fund

9.52%

Research Firm

0.32%

Individual Investor

0.25%

Sovereign Wealth Fund

0.05%

其他

34.36%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

290

16.78M

61.62%

-1.23M

2025Q2

295

16.40M

99.19%

-1.13M

2025Q1

309

29.14M

109.47%

+11.54M

2024Q4

309

140.52M

106.54%

+100.36M

2024Q3

304

31.22M

87.82%

-13.95M

2024Q2

305

33.18M

93.85%

-9.52M

2024Q1

295

33.76M

95.60%

-5.47M

2023Q4

282

36.46M

106.02%

-3.53M

2023Q3

281

36.40M

105.98%

-3.26M

2023Q2

295

35.63M

103.77%

-4.21M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Medicxi Ventures (UK) LLP

2.79M

16.89%

Jun 30, 2025

Forbion Capital Partners

440.18K

2.66%

+440.18K

Jun 30, 2025

TCG Crossover Management, LLC

1.64M

9.89%

Jun 30, 2025

Foresite Capital Management, LLC

1.56M

9.45%

Jun 30, 2025

RTW Investments L.P.

1.47M

8.89%

-1.00

-0.00%

Jun 30, 2025

OrbiMed Advisors, LLC

1.64M

9.93%

-2.00

-0.00%

Jun 30, 2025

Deep Track Capital LP

751.42K

4.54%

-1.00

-0.00%

Jun 30, 2025

The Vanguard Group, Inc.

880.05K

5.32%

-154.80K

-14.96%

Jun 30, 2025

Nantahala Capital Management, LLC

951.61K

5.75%

+325.00K

+51.87%

Jun 30, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

Invesco Dorsey Wright SmallCap Momentum ETF

0.56%

Avantis US Small Cap Equity ETF

0.02%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

Schwab U.S. Broad Market ETF

Blueprint Chesapeake Multi-Asset Trend ETF

Virtus LifeSci Biotech Clinical Trials ETF

DFA Dimensional US Core Equity Market ETF

iShares Russell 3000 ETF

Pacer WealthShield ETF

T Rowe Price Small-Mid Cap ETF

Invesco Dorsey Wright SmallCap Momentum ETF

占比0.56%

Avantis US Small Cap Equity ETF

占比0.02%

Invesco RAFI US 1500 Small-Mid ETF

占比0.01%

Schwab U.S. Broad Market ETF

占比0%

Blueprint Chesapeake Multi-Asset Trend ETF

占比0%

Virtus LifeSci Biotech Clinical Trials ETF

占比0%

DFA Dimensional US Core Equity Market ETF

占比0%

iShares Russell 3000 ETF

占比0%

Pacer WealthShield ETF

占比0%

T Rowe Price Small-Mid Cap ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Jun 13, 2025

Merger

8→1

公告日期

类型

比率

Jun 13, 2025

Merger

8→1

常见问题

RAPT Therapeutics Inc的前五大股东是谁？



RAPT Therapeutics Inc 的前五大股东如下：
Medicxi Ventures (UK) LLP持有股份：2.79M，占总股份比例：16.89%。
Forbion Capital Partners持有股份：440.18K，占总股份比例：2.66%。
TCG Crossover Management, LLC持有股份：1.64M，占总股份比例：9.89%。
Foresite Capital Management, LLC持有股份：1.56M，占总股份比例：9.45%。
RTW Investments L.P.持有股份：1.47M，占总股份比例：8.89%。